Dimensional Fund Advisors’s Summit Therapeutics SMMT Stock Holding History

Dimensional Fund Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86M	Buy	127,978 +39,482	+45%	+$700K	﹤0.01%	2756
2026 Q1	$1.67M	Sell	88,496 -288,067	-76%	-$4.66M	﹤0.01%	2743
2025 Q4	$6.59M	Buy	376,563 +1,980	+0.5%	+$37.3K	﹤0.01%	2440
2025 Q3	$7.74M	Sell	374,583 -5,421	-1%	-$131K	﹤0.01%	2393
2025 Q2	$8.08M	Buy	380,004 +93,975	+33%	+$2.14M	﹤0.01%	2349
2025 Q1	$5.52M	Buy	286,029 +80,692	+39%	+$1.62M	﹤0.01%	2467
2024 Q4	$3.66M	Buy	205,337 +160,592	+359%	+$3.11M	﹤0.01%	2627
2024 Q3	$980K	Buy	+44,745	New	+$626K	﹤0.01%	2910

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Dimensional Fund Advisors's SMMT Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Summit Therapeutics (SMMT) stake by 45% in Q2 2026, buying an estimated $700K and bringing the position to 127,978 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

Dimensional Fund Advisors first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $8.08M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Dimensional Fund Advisors held 127,978 shares of Summit Therapeutics worth $1.86M as of Q2 2026.
Dimensional Fund Advisors bought 39,482 Summit Therapeutics shares in Q2 2026, an estimated $700K.
Summit Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2756 holding.
Dimensional Fund Advisors first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
Dimensional Fund Advisors's Summit Therapeutics position peaked at $8.08M in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.